



Press Release

MSN Group launches 'FAVILOW' the most affordable Favipiravir in India for the treatment of Covid-19.

- **World's most affordable Favipiravir**
- **Cost 33 INR per tablet**
- **Available in pharmacies across India**
- **MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com**

Hyderabad, 13th August 2020: MSN Group (MSN), India's leading generic pharmaceutical company, announced today that it has launched the most affordable Favipiravir, marketed under the brand name 'FAVILOW'. The medicine will be costing 33 INR with recommended dose being 200 mg and will be available in all the pharmacies across India.

MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW through its own in-house R&D team. The medicine can be used for the treatment of mild to moderate COVID-19 patients.

Dr MSN Reddy, CMD – MSN Group, commented “We are glad to launch our product FAVILOW, during current tough times as COVID 19 cases in India are increasing like never before. We as a company always believe that quality medicine has to be accessible and available to everyone. We are confident that our product will nurture hope in patients as it is both effective and affordable at the same time.

The drug 'Favipiravir' has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalized with severe symptoms of the disease. FAVILOW (Favipiravir) will be available in 200 mg tablets which have to be purchased at medical and hospital pharmacies with a prescription by a healthcare practitioner.

As part of the COVID treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name “OSELOW”. MSN will also be launching FAVILOW 400 mg very soon in the market.

For availability, please contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com